Professor Rosenfeld graduated in physics before undertaking a PhD in Systems Biology at the Weizmann Institute of Science in Israel. He then switched fields to translational cancer research while working at Rosetta Genomics. He held different roles at the organisation, including Head of Computational Biology, in which he designed diagnostic algorithms and clinical assays for cancer classification. After moving to the UK in 2009, Professor Rosenfeld set up the Molecular and Computational Diagnostics Lab at the Cancer Research UK (CRUK) Cambridge Institute and led ground-breaking research on circulating tumour DNA (ctDNA), driving the rapidly growing field of liquid biopsies for cancer. He is co-inventor of multiple patents on the use of microRNA and cell-free DNA in cancer diagnostics that have been deployed as clinical diagnostic tests. In 2014 he co-founded Inivata, a clinical cancer genomics company which quickly grew to 150 employees, raised over $150m and was eventually acquired by NeoGenomics for total of $415m.